Top Page
Alvotech
(NASDAQ:ALVO)
Alvotech (ALVO) vs. SPDR S&P 500 ETF (SPY)
Alvotech Business Overview & Revenue Model
Alvotech Earnings Call Summary
Alvotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.10M | 489.68M | 91.43M | 83.03M | 36.77M | 66.62M |
| Gross Profit | 300.68M | 304.37M | -69.42M | 18.93M | 36.77M | 66.62M |
| EBITDA | 207.20M | -28.66M | -484.86M | -439.80M | 3.99M | -125.67M |
| Net Income | 63.36M | -231.86M | -551.73M | -513.58M | -101.50M | -170.04M |
Balance Sheet | ||||||
| Total Assets | 1.39B | 1.22B | 950.09M | 828.44M | 597.98M | 474.42M |
| Cash, Cash Equivalents and Short-Term Investments | 151.45M | 51.43M | 11.16M | 66.43M | 17.56M | 31.69M |
| Total Debt | 1.27B | 1.19B | 1.08B | 805.10M | 523.05M | 676.85M |
| Total Liabilities | 1.57B | 1.63B | 1.88B | 1.39B | 733.59M | 1.34B |
| Stockholders Equity | -173.33M | -412.77M | -932.49M | -564.42M | -135.61M | -867.24M |
Cash Flow | ||||||
| Free Cash Flow | -139.82M | -293.84M | -358.66M | -361.39M | -268.80M | -86.28M |
| Operating Cash Flow | -42.55M | -236.84M | -312.19M | -312.39M | -228.17M | -74.30M |
| Investing Cash Flow | -57.30M | -18.87M | -46.34M | -63.54M | -40.63M | -16.90M |
| Financing Cash Flow | 237.43M | 297.31M | 301.32M | 424.91M | 254.83M | 55.40M |
Alvotech Technical Analysis
Alvotech Risk Analysis
Alvotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $2.64B | 41.10 | 6.06% | ― | 5.55% | 1145.24% | |
66 Neutral | $2.02B | -121.05 | -2.53% | ― | 38.68% | -160.14% | |
66 Neutral | $2.75B | 5.83 | 4.96% | ― | -1.35% | ― | |
66 Neutral | $3.06B | 1,523.44 | -3.00% | ― | 9.81% | ― | |
52 Neutral | $2.52B | 39.73 | 128.44% | ― | 98.37% | ― | |
51 Neutral | $2.95B | -38.39 | -1.80% | 5.34% | -2.32% | 35.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Alvotech Corporate Events
On September 19, 2025, Alvotech announced that its partner in Japan, Fuji Pharma, received marketing authorization for three biosimilars from the Japanese Ministry of Health, Labor and Welfare. These biosimilars, AVT03, AVT05, and AVT06, target bone lesions, rheumatoid arthritis, and macular degeneration, respectively. Additionally, on September 22, 2025, Alvotech announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval for AVT03 and AVT05 in the European Economic Area, pending a final decision by the European Commission. These developments are significant for Alvotech’s expansion in the Japanese and European markets, enhancing its industry positioning and offering potential benefits for stakeholders.
Alvotech reported financial results for the first half of 2025, showing a significant increase in product revenue to $204.7 million compared to $65.9 million in the same period in 2024, driven by the expansion of AVT02 and the launch of AVT04 in multiple countries. Despite a decrease in license and other revenue, the company achieved a net profit of $141.7 million, a substantial turnaround from a net loss in the previous year. Alvotech also announced several strategic initiatives, including a collaboration with Dr. Reddy’s Laboratories for a Keytruda biosimilar and an expanded partnership with Advanz Pharma for additional biosimilar candidates, positioning the company for further growth in the biosimilars market.
In recent developments, Alvotech has made significant strides in its business operations and strategic partnerships. On June 25, 2025, the company re-elected six members to its Board of Directors and appointed a new Chief Financial Officer, Linda Jonsdottir, who brings extensive experience in finance and corporate leadership. Alvotech has also expanded its commercial partnership with Advanz Pharma and entered into a collaboration with Dr. Reddy’s Laboratories for biosimilar candidates. Additionally, the company acquired Ivers-Lee Group to enhance its technical operations. Regulatory progress includes a positive opinion from the European Medicines Agency for a biosimilar to Eylea and successful study results for a biosimilar to Xolair. However, a recent FDA inspection highlighted some deficiencies in manufacturing operations, which Alvotech is addressing. Financially, Alvotech completed an oversubscribed offering of Swedish Depository Receipts and a private placement, raising substantial funds to support its growth initiatives.
On July 10, 2025, Alvotech announced the appointment of Linda Jónsdóttir as the new Chief Financial Officer, succeeding Joel Morales. Linda brings extensive experience in finance and corporate leadership, having held senior roles in various industries. Joel Morales, who has been with Alvotech since 2020, will continue in an advisory role to ensure a smooth transition. This leadership change is significant for Alvotech as it continues its growth trajectory and aims to strengthen its position as a global leader in the biosimilar industry.
On July 9, 2025, Alvotech announced its acquisition of Ivers-Lee Group, a Swiss company specializing in pharmaceutical assembly and packaging services. This acquisition is set to enhance Alvotech’s capacity and flexibility in meeting the growing global demand for biosimilars, supporting its plans to launch three new biosimilars in 2025. The integration of Ivers-Lee into Alvotech’s operations is expected to provide stability and growth opportunities for both companies, while maintaining high-quality service for existing clients.
On July 1, 2025, Alvotech announced a commercialization agreement with Advanz Pharma for the distribution and supply of AVT10, a biosimilar candidate to Cimzia, in Europe. This agreement strengthens Alvotech’s strategic position in the biosimilar market and aims to expand access to high-quality biologics in Europe, potentially impacting the market share of existing treatments for chronic rheumatic diseases.